AIM ImmunoTech reports 50% response rate in ovarian cancer trial

May 7, 2026 8:23 AM

AIM ImmunoTech Inc. (NYSE American: AIM) announced results from a University of Pittsburgh Medical Center Phase 2 clinical trial evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found